237 related articles for article (PubMed ID: 34521767)
1. Tetraspanin 6 is a regulator of carcinogenesis in colorectal cancer.
Andrijes R; Hejmadi RK; Pugh M; Rajesh S; Novitskaya V; Ibrahim M; Overduin M; Tselepis C; Middleton GW; Győrffy B; Beggs AD; Berditchevski F
Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34521767
[TBL] [Abstract][Full Text] [Related]
2. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
3. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
Gbenedio OM; Bonnans C; Grun D; Wang CY; Hatch AJ; Mahoney MR; Barras D; Matli M; Miao Y; Garcia KC; Tejpar S; Delorenzi M; Venook AP; Nixon AB; Warren RS; Roose JP; Depeille P
JCI Insight; 2019 Jun; 5(15):. PubMed ID: 31237864
[TBL] [Abstract][Full Text] [Related]
4. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
[TBL] [Abstract][Full Text] [Related]
5. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
[TBL] [Abstract][Full Text] [Related]
6. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
7. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data.
Guo GF; Wang YX; Zhang YJ; Chen XX; Lu JB; Wang HH; Jiang C; Qiu HQ; Xia LP
World J Gastroenterol; 2019 Apr; 25(15):1840-1853. PubMed ID: 31057298
[TBL] [Abstract][Full Text] [Related]
8. Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong?
Weinberg BA
J Natl Compr Canc Netw; 2018 Dec; 16(12):1547-1548. PubMed ID: 30545999
[No Abstract] [Full Text] [Related]
9. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
[TBL] [Abstract][Full Text] [Related]
10. TSPAN6 is a suppressor of Ras-driven cancer.
Humbert PO; Pryjda TZ; Pranjic B; Farrell A; Fujikura K; de Matos Simoes R; Karim R; Kozieradzki I; Cronin SJF; Neely GG; Meyer TF; Hagelkruys A; Richardson HE; Penninger JM
Oncogene; 2022 Apr; 41(14):2095-2105. PubMed ID: 35184157
[TBL] [Abstract][Full Text] [Related]
11. Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR.
Du F; Qiao C; Li X; Chen Z; Liu H; Wu S; Hu S; Qiu Z; Qian M; Tian D; Wu K; Fan D; Nie Y; Xia L
Theranostics; 2019; 9(13):3879-3902. PubMed ID: 31281520
[No Abstract] [Full Text] [Related]
12. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Siena S; Sartore-Bianchi A; Di Nicolantonio F; Balfour J; Bardelli A
J Natl Cancer Inst; 2009 Oct; 101(19):1308-24. PubMed ID: 19738166
[TBL] [Abstract][Full Text] [Related]
14. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells.
Liu BS; Xia HW; Zhou S; Liu Q; Tang QL; Bi NX; Zhou JT; Gong QY; Nie YZ; Bi F
Oncol Rep; 2018 Oct; 40(4):2171-2182. PubMed ID: 30106444
[TBL] [Abstract][Full Text] [Related]
16. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
[TBL] [Abstract][Full Text] [Related]
17. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
[TBL] [Abstract][Full Text] [Related]
18. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.
McFall T; Diedrich JK; Mengistu M; Littlechild SL; Paskvan KV; Sisk-Hackworth L; Moresco JJ; Shaw AS; Stites EC
Sci Signal; 2019 Sep; 12(600):. PubMed ID: 31551296
[TBL] [Abstract][Full Text] [Related]
19. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.
Vangala D; Ladigan S; Liffers ST; Noseir S; Maghnouj A; Götze TM; Verdoodt B; Klein-Scory S; Godfrey L; Zowada MK; Huerta M; Edelstein DL; de Villarreal JM; Marqués M; Kumbrink J; Jung A; Schiergens T; Werner J; Heinemann V; Stintzing S; Lindoerfer D; Mansmann U; Pohl M; Teschendorf C; Bernhardt C; Wolters H; Stern J; Usta S; Viebahn R; Admard J; Casadei N; Fröhling S; Ball CR; Siveke JT; Glimm H; Tannapfel A; Schmiegel W; Hahn SA
Genome Med; 2021 Jul; 13(1):116. PubMed ID: 34271981
[TBL] [Abstract][Full Text] [Related]
20. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
